Max A. Hietala
Solna, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
MEK inhibition in adult patients with pilocytic astrocytomas.
Journal: NPJ precision oncology
Published: October 11, 2025
Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.
Journal: European journal of neurology
Published: July 08, 2025
Glial fibrillary acidic protein in cerebrospinal fluid in humans is sensitive to various pre-analytical conditions: possible explanation and solution.
Journal: Frontiers in neurology
Published: May 12, 2025
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Journal: JAMA neurology
Published: May 05, 2020
Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: December 16, 2019
Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome.
Journal: Journal of neuroimmunology
Published: August 02, 2019
Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.
Journal: Journal of medical case reports
Published: September 05, 2018
The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis.
Journal: Frontiers in neurology
Published: October 05, 2017
Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: October 04, 2017
Heroin-induced acute myelopathy with extreme high levels of CSF glial fibrillar acidic protein indicating a toxic effect on astrocytes.
Journal: BMJ case reports
Published: June 30, 2017
Last Updated: 09/26/2026